Prognostic analysis of ERCC1, RRM1 and p53 expressions in postoperative stage I - II lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 5, 2009, Pages 387-395

  Wang, Huimin ^a   Feng, Jiuxián ^a   Zhang, Xueyan ^a   Yang, Xiaohua ^a   He, Weizhong ^a   Sha, Huifang ^a   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Drug resistance; Human ERCC1 protein; Human RRM1 protein; Lung neoplasms; Prognosis; Tumor suppressor protein p53

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 67449085980     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.05.003     Document Type: Article

References (21)

1. Liao ML, Zhou YZ, Ding JA, et al. Studies on biological characteristics drug sensitivity testing and postoperative adjuvant therapy of NSCLC. Shanghai Med J, 1999, 22(12): 720-724.
2. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol, 2000, 60(9): 1305-1313. (Pubitemid 30734892)
3. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci, 2007, 98(9): 1336-1343.
4. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10(4): 1318-1325.
5. Rosell R, Cuello M, Cecere F, et al. Usefulness of predictive tests for cancer treatment. Bull Cancer, 2006, 93(8): E101-E108.
6. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17(12): 1818-1825.
7. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev, 2005, 14(2): 491-496.
8. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 2007, 356(8): 800-808.
9. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 2005, 127(3): 978-983.
10. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 2002, 8(7): 2286-2291.
11. Olaussen KA, Dunant A, Fouret P, et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355(10): 983-991.
12. Herrick J, Sclavi B. Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol Microbiol, 2007, 63(1): 22-34. (Pubitemid 44968106)
13. Heist RS, Liu G, Zhou W. Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer? Nat Clin Pract Oncol, 2007, 4(10): 564-565.
14. Liao RQ, Lin JY, Qiao GB, et al. RRM1 expression in tissue microarray and prognosis analysis in non-small cell lung cancer. Chin J Lung Cancer, 2006, 9(5): 423-427.
15. Rui M, Li LY, Liu CT. Correlation between several biological parameters and 5-year survival rate in patients with lung cancer. Chin J Clin Rehabil, 2006, 10(28): 67-69. (Pubitemid 44240957)
16. Tao H, Zhu YZ, Wang H, et al. Effects of p53 gene on drug resistance in human lung cancer cell lines. Chin J Cancer, 2008, 11(2): 157-164.
17. Gregore V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance, to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer, 2003, 39(1): 41-48.
18. Song Y, Zuo Y, Chen YN. The expression and clinical significance of surviving, p53 and p21 in the non-small cell lung cancer. Chin Clin Oncol, 2008, 13(9): 788-791.
19. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res, 2000, 6(10): 4055-4563. (Pubitemid 30807100)
20. Yue WT, Lai BT, Wang H, et al. P53 gene mutation in lung cancer and their effect on patients' survival and metastasis. Beijing Med J, 2000, 22(3): 138-141.
21. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage I B non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I, 2006, 24(18): 7007.